U
Universal Diagnostics
Development of diagnostics tests for early cancer detection
About Universal Diagnostics
UniversalDx is a health-tech startup that operates in the medical diagnostics market, specifically focusing on cancer detection. The company has developed a liquid biopsy test, Signal-C®, which can accurately detect Colorectal Cancer and Advanced Adenomas. This test uses a combination of multi-omics, computational biology, and machine learning to identify cancer signals, boasting a sensitivity of 92% and a specificity of 94%. In simpler terms, this means the test is highly accurate in both identifying those who have the disease (sensitivity) and correctly ruling out those who do not (specificity).
The company's primary clients are healthcare providers and patients who require cancer screening. UniversalDx's business model revolves around providing this innovative diagnostic tool to the healthcare sector. They generate revenue by selling the Signal-C® test to healthcare providers or directly to patients.
A significant part of their strategy is their collaboration with Quest Diagnostics, a leading provider of diagnostic information services. This partnership will help UniversalDx to accelerate the impact of their cancer detection test and increase its availability. Once the Signal-C® test receives FDA approval, it will be accessible through the Quest Diagnostics network, allowing a larger share of the U.S. population to be screened for colorectal cancer. This could potentially reduce both the incidence and mortality rates of this disease.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Seville, Spain
- Employees
- 125
- Open positions
- 23
- Dealroom signal
- 71.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Oncology, Core AI, Metabolism, Sustainable Development Goals, Hard Tech, AI Applications, Horizon Europe
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Jan 2026 | $33M | — | Government of Spain | ↗ |
| LATE VCOther financing | May 2025 | $0 | — | Arcano Partners | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Universal Diagnostics is 3.9K monthly website visits, up 34.5% over the last three months. Universal Diagnostics's team grew 5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
European Innovation Council
Government of Spain
Series A2 investors entered at this stage
Quest Diagnostics
Olympus Innovation Ventures
Series B and later2 investors entered at this stage
European Investment Bank
Arcano Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Universal Diagnostics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Universal Diagnostics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.